Betulinic acid nanoformulation - Aphios Corporation
Alternative Names: APH-0202Latest Information Update: 28 May 2025
At a glance
- Originator Aphios Corporation
- Class Anti-inflammatories; Antineoplastics; Antiretrovirals; Triterpenes
- Mechanism of Action Apoprotein stimulants; Caspase stimulants; HIV fusion inhibitors; HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 May 2025 No recent reports of development identified for research development in HIV-infections in USA (PO)
- 29 Apr 2021 Betulinic acid nanoformulation - Aphios Corporation is available for licensing as of 29 Apr 2021. https://aphios.com/partnering/partnering-overview/
- 08 Apr 2021 Early research in HIV infections in USA (PO) before April 2021 (Aphios Corporation pipeline, April 2021)